Rankings
▼
Calendar
DNLI Q2 2021 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena
DNLI
Denali Therapeutics Inc.
$3B
Q2 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$23M
+292.3% YoY
Gross Profit
$23M
100.0% margin
Operating Income
-$62M
-269.5% margin
Net Income
-$61M
-264.6% margin
EPS (Diluted)
$-0.49
QoQ Revenue Growth
+189.5%
Cash Flow
Operating Cash Flow
-$54M
Free Cash Flow
-$55M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$1.5B
Total Liabilities
$437M
Stockholders' Equity
$1.1B
Cash & Equivalents
$486M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$23M
$6M
+292.3%
Gross Profit
$23M
$6M
+292.3%
Operating Income
-$62M
-$61M
-0.9%
Net Income
-$61M
-$59M
-3.3%
Revenue Segments
Alzheimer's Disease Services
$3M
100%
← FY 2021
All Quarters
Q3 2021 →